XNASPSTX
Market cap925mUSD
Jan 07, Last price
9.50USD
1D
-0.63%
1Q
271.09%
IPO
-29.53%
Name
Poseida Therapeutics Inc
Chart & Performance
P/E
—
P/S
14.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.21%
Rev. gr., 5y
112.83%
Revenues
65m
-50.37%
Net income
-123m
L+92.85%
CFO
-92m
L+244.27%
Earnings
Mar 05, 2025
Profile
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 64,703 -50.37% | 130,362 417,217.08% | ||||||
Cost of revenue | 350,979 | 195,610 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (286,276) | (65,248) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 107 | 544 | ||||||
Tax Rate | ||||||||
NOPAT | (286,383) | (65,792) | ||||||
Net income | (123,430) 92.85% | (64,002) -1,553.31% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 15,345 | 75,299 | ||||||
BB yield | -5.06% | -19.75% | ||||||
| Debt | ||||||||
Debt current | 11,902 | 5,866 | ||||||
Long-term debt | 106,305 | 113,388 | ||||||
Deferred revenue | 16,780 | 21,333 | ||||||
Other long-term liabilities | 2,614 | 6,083 | ||||||
Net debt | (93,995) | (154,015) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (92,167) | (26,772) | ||||||
CAPEX | (3,066) | (3,924) | ||||||
Cash from investing activities | 39,134 | (203,334) | ||||||
Cash from financing activities | 16,127 | 105,159 | ||||||
FCF | (280,493) | (64,236) | ||||||
| Balance | ||||||||
Cash | 212,202 | 282,493 | ||||||
Long term investments | (9,224) | |||||||
Excess cash | 208,967 | 266,751 | ||||||
Stockholders' equity | (594,155) | (471,001) | ||||||
Invested Capital | 808,624 | 774,764 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 90,185 | 71,954 | ||||||
Price | 3.36 -36.60% | 5.30 -22.17% | ||||||
Market cap | 303,022 -20.54% | 381,355 -10.02% | ||||||
EV | 209,027 | 227,340 | ||||||
EBITDA | (280,662) | (60,076) | ||||||
EV/EBITDA | ||||||||
Interest | 8,671 | 6,370 | ||||||
Interest/NOPBT | ||||||||